8-K: Equillium Announces Mixed Phase 3 Results and Submits Breakthrough Therapy Request to FDA

Equillium reports topline data from its Phase 3 EQUATOR study, highlighting statistically significant longer-term benefits of itolizumab in aGVHD despite not meeting the primary endpoint, and submits a request for Breakthrough Therapy designation to the FDA.

Summary

• Equillium announced its financial results for the fourth quarter and full year 2024.
• The company also announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of acute graft-versus-host disease (aGVHD).
• The study did not meet the primary endpoint of complete response at Day 29, but itolizumab showed statistically significant and clinically meaningful benefit in longer-term outcomes.
• These outcomes include complete response at Day 99, duration of complete response, and failure-free survival.
• Equillium has submitted a request for Breakthrough Therapy designation to the FDA and expects feedback in May 2025.
• If the feedback is positive and subject to raising additional capital, the company plans to submit a biologics license application (BLA) in the first half of 2026.
• Revenue for Q4 2024 was $4.4 million, compared to $9.2 million in Q4 2023.
• Full-year 2024 revenue was $41.1 million, compared to $36.1 million in 2023.
• The revenue consisted of itolizumab development funding and amortization of the upfront payment from Ono Pharmaceutical.
• Research and development (R&D) expenses for Q4 2024 were $7.3 million, compared to $9.2 million in Q4 2023.
• For the full year 2024, R&D expenses were $37.4 million, compared to $37.0 million in 2023.
• General and administrative (G&A) expenses for Q4 2024 were $1.8 million, compared to $3.2 million in Q4 2023.
• For the full year 2024, G&A expenses were $11.9 million, compared to $13.6 million in 2023.
• Net loss for Q4 2024 was $5.8 million, or $(0.16) per share, compared to a net loss of $2.3 million, or $(0.07) per share in Q4 2023.
• Net loss for the full year 2024 was $8.1 million, or $(0.23) per share, compared to a net loss of $13.3 million, or $(0.38) per share in 2023.
• Cash, cash equivalents, and short-term investments totaled $22.6 million as of December 31, 2024, compared to $40.9 million as of December 31, 2023.
• Equillium believes its cash will fund operations into the third quarter of 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the primary endpoint was not met, there were positive longer-term outcomes and a Breakthrough Therapy designation request. However, the company needs to raise additional capital and cash reserves are declining.

Positives

• Itolizumab demonstrated statistically significant and clinically meaningful benefit in longer-term outcomes in the Phase 3 EQUATOR study.
• The company has submitted a request for Breakthrough Therapy designation to the FDA.
• Full-year 2024 revenue increased compared to 2023.
• Net loss for the full year 2024 decreased compared to 2023.
• Positive topline data from a Phase 2 study evaluating itolizumab in the treatment of moderate to severe ulcerative colitis (UC) was announced.
• Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo.

Negatives

• The Phase 3 EQUATOR study did not meet the primary endpoint of complete response at Day 29.
• Cash, cash equivalents, and short-term investments decreased from $40.9 million to $22.6 million year-over-year.
• The company's cash is expected to fund operations only into the third quarter of 2025, necessitating additional capital.

Risks

• The company's ability to raise additional capital is uncertain.
• The FDA may not grant Breakthrough Therapy designation or Accelerated Approval for itolizumab.
• Clinical and pre-clinical studies may not validate the safety and efficacy of Equillium's product candidates.
• Changes in the competitive landscape could impact Equillium's strategic plans.
• The company's ability to continue as a going concern is dependent on raising additional capital.

Future Outlook

Equillium anticipates feedback from the FDA on its request for Breakthrough Therapy designation in May 2025 and plans to submit a BLA in the first half of 2026, contingent on positive feedback and securing additional capital. The company believes its current cash reserves can fund operations into the third quarter of 2025.

Management Comments

• Bruce Steel, chief executive officer at Equillium, stated that while the Phase 3 EQUATOR study did not meet the primary endpoint, itolizumab demonstrated statistically significant and clinically meaningful benefit in important longer-term outcomes.

Industry Context

Equillium is developing itolizumab for severe autoimmune and inflammatory disorders. The aGVHD market has a high unmet need, with limited approved therapies and poor overall survival rates. The company's pursuit of Breakthrough Therapy designation and Accelerated Approval pathway reflects the urgency to address this unmet need.

Comparison to Industry Standards

• The reported clinical remission rate of 23.3% for itolizumab in ulcerative colitis after 12 weeks of treatment is comparable to the 20.0% achieved by adalimumab in the same study.
• Adalimumab (Humira) is a widely used TNF inhibitor for ulcerative colitis, and the similar efficacy suggests itolizumab could be a competitive alternative.
• However, it's important to note that clinical trial results can vary, and direct comparisons to other studies with different patient populations and endpoints should be made cautiously.
• Companies like Takeda (Entyvio) and Pfizer (Xeljanz) also have approved therapies for ulcerative colitis, and itolizumab would need to demonstrate a clear advantage in efficacy, safety, or patient convenience to gain significant market share.

Stakeholder Impact

• Shareholders: The mixed results of the Phase 3 trial could lead to uncertainty in the stock price.
• Patients: Positive longer-term outcomes offer hope for a new treatment option for aGVHD.
• Employees: The need to raise additional capital could impact job security.
• Partners: The potential BLA submission could strengthen partnerships and collaborations.

Next Steps

• Await feedback from the FDA on the request for Breakthrough Therapy designation in May 2025.
• Potentially submit a biologics license application (BLA) in the first half of 2026, subject to positive FDA feedback and raising additional capital.
• Continue clinical development of itolizumab in other indications, such as ulcerative colitis.
• Continue to develop EQ302.

Key Dates

Keywords

itolizumab, EQUATOR study, graft-versus-host disease, aGVHD, Breakthrough Therapy designation, FDA, clinical trial, financial results, Equillium, biotechnology